Investigational New Drugs **10:** 359–362, 1992.

CONTENTS VOL. 10, 1992

Preclinical Studies

An efficient multiple-exposure analysis of the toxicity of crisnatol, a DNA intercalator in phase II clinical trials – R.M. Zucker, D.J. Adams, K.W. Bair, K.H. Elstein 1

Activity of a recombinant transforming growth factor-α-*Pseudomonas* exotoxin hybrid protein against primary human tumor colony-forming units – D.D. Von Hoff, M.H. Marshall, D.C. Heimbrook, S.M. Stirdivant, J.D. Ahern, W.K. Herbert, R.Z. Maigetter, A. Oliff 17

Clinical Studies

Phase II trial of didemnin-B in advanced epithelial ovarian cancer. *A Southwest Oncology Group study* – J.M. Cain, P.Y. Liu, D.E. Alberts, H.H. Gallion, L. Laufman, J. O'Sullivan, G. Weiss, J.N. Bickers 23

Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix. *A Phase II trial of the Gynecologic Oncology Group (GOG)* – H.B. Muss, J.A. Blessing, G.L. Eddy, R. McGehee 25

Brief Reports

Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. *An Illinois Cancer Council Study* – T. Lad, J. Schor, M. Mullane, R. Carroll, D. Chernicoff, R. Blough, L. Weidner 27

Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. *A Southwest Oncology Group study* – S.K. Williamson, J.J. Crowley, R. Livingston, A. Hantel, J.H. Doroshow 29

Phase II study of 10-EdAM in patients with squamous cell carcinoma of the head and neck, previously untreated with chemotherapy – M.D. Green, P. Sherman, J. Zalcberg 31

Menogaril in the treatment of relapsed multiple myeloma. *A Phase II trial of the Cancer Center of Wake Forest University* – J.M. Cruz, L.D. Case, H.B. Dalton, W.L. Ramseur, F. Richards, II, D.V. Jackson, H.B. Muss, P.J. Zekan, R.A. Brodkin, R.C. Brown, W.B. Herring, J.A. Lusk, M.A. O'Rourke, S.M. Reddy, R.L. Capizzi 35

Phase II trial of fazarabine in advanced colorectal carcinoma – K.P. Hubbard, K. Daughterty, J.A. Ajani, R. Pazdur, B. Levin, J.L. Abbruzzese 39

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer – R.S. Walters, R.L. Theriault, F.A. Holmes, G.N. Hortobagyi, L. Esparza 43

Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose Melphalan with autologous bone marrow transplantation – W.J. Slichenmyer, C.F. LeMaistre, D.D. Von Hoff 45

Evaluation of deoxycoformycin in patients with advanced renal cell carcinoma. *An ECOG pilot study* – R.S. Witte, C. Walsh, H. Fisher, M.M. Okem, D.J. Reding, D.L. Trump 49

Trimetrexate in advanced renal cell carcinoma. *An ECOG Phase II trial* – R.S. Witte, P. Elson, G.T. Bryan, D.L. Trump 51

Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. *A Southwest Oncology Group study* – S.A. Taylor, P. Goodman, E.D. Crawford, W.J. Stuckey, R.L. Stephens, E.R. Gaynor 55

Announcements 57

Preclinical Studies

Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells – V. Wiebe, S. Koester, M. Lindberg, V. Emshoff, J. Baker, G. Wurz, M. DeGregorio 63

Evaluation of *in vitro* drug screening leads using experimental models of human ovarian cancer – K.G. Louie, T.C. Hamilton, R.H. Shoemaker, R.C. Young, R.F. Ozols 73

Bis-daunomycin hydrazones: Interactions with DNA – D.R. Phillips, R.T.C. Brownlee, J.A. Reiss, P.A. Scourides 79

Clinical Studies

Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck – F. Kruter, M. Eisenberger, V. Sinibaldi, C. Engstrom, M. Jacobs, J.

Abrams, C. Belani, W. Gray, S. Krasnow 89

Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. *A phase II study (Pediatric Oncology Group)* – R. Nitschke, C. Pratt, M. Harris, J. Krischer, T.J. Vietti, H. Grier, W. Kamps, S. Toledano 93

Oral piritrexim – A phase II study in patients with advanced soft tissue sarcoma – J.D. Schiesel, M. Carabasi, G. Magill, E. Casper, E. Cheng, L. Marks, J. Feyzi, N.J. Clendeninn, R.V. Smalley 97

Phase II study of amonafide in advanced and recurrent sarcoma patients – R.P. Perez, S.L. Nash, R.F. Ozols, R.L. Comis, P.J. O'Dwyer 99

Menogaril in the treatment of malignant mesothelioma: A phase II study – C.A. Hudis, D.P. Kelsen 103

A phase II study of crisnatol mesylate in patients with ovarian carcinoma – R.V. Smalley, D. Goldstein, D. Bulkowski, C. Hannon, D. Buchler, C. Knudsen, R.L. Tuttle 107

Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer – J.A. Benvenuto, R.A. Newman, G.S. Bignami, T.J.G. Raybould, M.N. Raber, L. Esparza, R.S. Walters 113

Phase II clinical study of pirarubicin in hormone resistant prostate cancer – B.L. Rapoport, G. Falkson 119

Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer – R. Rosell, J. Carles, A. Abad, J.M. Jimeno, I. Moreno, A. Barnadas, N. Ribelles, N. Haboubi 123

Phase II evaluation of piroxantrone in renal cell carcinoma. *A Southwest Oncology Group Study* – A. Allen, M. Wolf, E.D. Crawford, M.P. Davis, R.B. Natale, M.L. Barnett 129

Announcement 133

Preclinical Studies

In vitro and *in vivo* circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative – A. Pierré, T.A. Dunn, L. Kraus-Berthier, S. Léonce, D. Saint-Dizier, G. Régnier, A. Dhainaut, M. Berlion, J.-P. Bizzari, G. Atassi 137

Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model – P.M. Loadman, M.C. Bibby, J.A. Double, R.S. McElhinney 149

Clinical Studies

Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors – N.C. Munshi, P.J. Loehrer, Sr., S.D. Williams, C. Langefeld, G. Sledge, C.R. Nichols, B.J. Roth, A. Neuman, W.B. Walsh, L.H. Einhorn 159

Difluorodeoxycytidine (dFdC) – gemcitabine: A phase I study – E.A. Poplin, T. Corbett, Lawrence Flaherty, Peter Tarasoff, B.G. Redman, M. Valdivieso, L. Baker 165

Phase I study of mitonafide in 120 hour continuous infusion in a non-small cell lung cancer – R. Rosell, J. Carles, A. Abad, N. Ribelles, A. Barnadas, A. Benavides, M. Martín 171

Phase I study of mitonafide in solid tumors – A. Poveda, M. Llombart, E. Forner, C. Fernández-Martos, C. Gaspar, M. Muñoz, T. Olmos, A. Ruiz, V. Soriano, A. Benavides, M. Martin, E. Schlick, V. Guillem 177

A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion – A. Mittelman, C. Puccio, E. Gafney, N. Coombe, B. Singh, D. Wood, P. Nadler, T. Ahmed, Z. Arlin 183

Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles – J. Kattan, J.-P. Droz, P. Couvreur, J.-P. Marino, A. Boutan-Laroze, P. Rougier, P. Brault, H. Vranckx, J.-M. Grognet, X. Morge, H. Sancho-Garnier 191

Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas – L.J. Kilton, A.B. Benson III, A. Greenberg, P. Johnson, C. Shapiro, R. Blough, S. French, L. Weidner 201

Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma – E.S. Casper, G.K. Schwartz, D.P. Kelsen 205

Phase II study of didemnin B in advanced colorectal cancer – D.V. Jones, Jr., J.A. Ajani, R. Blackburn, K. Daugherty, B. Levin, Y.Z. Patt, J.L. Abbruzzese 211

Phase II trial of N-methylformamide in lung cancer – R.L. Cody, J.E. Seid, R.B. Natale 215

A phase II study of interleukin-2 and interferon-alpha in head and neck cancer – S.P. Schantz, I. Dimery, S.M. Lippman, G.L. Clayman, C. Pellegrino, R. Morice 217

A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma – B.R. Murphy, S.M. Rynard, L.H. Einhorn, P.J. Loehrer 225

A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse – T. Vats, G. Buchanan, P. Mehta, A. Ragab, E. Hvizdale, R. Nitschke, M. Link. G.P. Beardsley, D. Maybee, J. Krischer 231

Announcements 235

Work of Special Interest

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria – S. Green, G.R. Weiss 239

Preclinical Studies

Comparative *in vitro* myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells – D.A. Volpe, D.-L. Du, M.G. Zurlo, N. Mongelli, M.J. Murphy 255

Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique – S. Urien, G. Bastian, C. Lucas, J.-P. Bizzari, J.-P. Tillement 263

Lack of effects of recombinant human interleukin-4 on *in vitro* colony formation of freshly explanted human tumor cells – A.-R. Hanauske, D. Degen, M.H. Marshall, P.P. Trotta, D.D. Von Hoff 264

Phase I Clinical Trials

Taxol administered as a 120 hour infusion – D.R. Spriggs, C. Tondini 275

Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days – H. Bailey, P. Kohler, R. Tuttle, P.P. Carbone, J.A. Hohneker, N.J. Clendeninn, G. Wilding 279

Clinical pharmacology studies of Oltipraz – A potential chemopreventive agent – N.V. Dimitrov, J.L. Bennett, J. McMillan, M. Perloff, C. Meyer Leece, W. Malone 289

Phase II Clinical Trials

Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer – M.D. Hauge, H.J. Long, L.C. Hartmann, J.H. Edmonson, M.J. Webb, J. Su 299

Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer – L. Kayitalire, F. Thomas, T. Le Chevalier, C. Toussaint, T. Tursz, M. Spielmann 303

A phase II trial of CI-921 in advanced malignancies – N.T. Sklarin, P.H. Wiernik, W.R. Grove, L. Benson, A. Mittelman, J.A. Maroun, J.A. Stewart, F. Robert, J.H. Doroshow, P.J. Rosen, J. Jolivet, J.C. Ruckdeschel, N.J. Robert, E. Vèlez-Garcìa, D.E. Bergsagel, L.C. Panasci, A.M. van der Merwe, J.J. Longueville, J. Leiby, C.D. Kowal 309

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma – E.S. Casper, G.K. Schwartz, B. Johnson, D.P. Kelsen 313

Phase II trial of pirarubicin in the treatment of advanced bladder cancer – M. Mahjoubi, J. Kattan, M. Ghosn, J.-P. Droz, I. Philippot, P. Herait 317

Phase II study of gemcitabine in advanced colorectal adenocarcinoma – D.F. Moore Jr., R. Pazdur, K. Daugherty, P. Tarassoff, J.L. Abbruzzese 323

Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT – B.A. Murphy, R.J. Motzer, G.J. Bosl 327

Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma – F.V. Fossella, R.J. Winn, P.Y. Holoye, B. Hallinan, M.N. Raber, K. Hoelzer, J.A. Young, J. Readling, B. Bowers, W.K. Hong 331

An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma – G. Falkson, M. Hunt, E.C. Borden, J.A. Hayes, C.I. Falkson, T.J. Smith 337

Brief Reports

A phase II investigation of pentostatin in metastatic malignant melanoma – M. Grever, P. Brager, E. Kraut, E. Metz 345

Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study – E.H. Kraut, J. Bendetti,

S.P. Balcerzak, J.H. Doroshow 347

Phase III and Maintenance Trials

Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma – A. Avilés, J.C. Díaz-Maqueo, E.L. García, A. Talavera, R. Guzmán 351

Announcement 357

Contents Volume 10, 1992 359

Author Index 363